Literature DB >> 27109782

Bone: Does anti-sclerostin therapy promote inflammation in rheumatoid arthritis?

Natalie A Sims1.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27109782     DOI: 10.1038/nrendo.2016.59

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis.

Authors:  B Y Chan; E S Fuller; A K Russell; S M Smith; M M Smith; M T Jackson; M A Cake; R A Read; J F Bateman; P N Sambrook; C B Little
Journal:  Osteoarthritis Cartilage       Date:  2011-05-12       Impact factor: 6.576

2.  Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction.

Authors:  Corinna Wehmeyer; Svetlana Frank; Denise Beckmann; Martin Böttcher; Christoph Cromme; Ulrich König; Michelle Fennen; Annelena Held; Peter Paruzel; Christine Hartmann; Athanasios Stratis; Adelheid Korb-Pap; Thomas Kamradt; Ina Kramer; Wim van den Berg; Michaela Kneissel; Thomas Pap; Berno Dankbar
Journal:  Sci Transl Med       Date:  2016-03-16       Impact factor: 17.956

3.  Romosozumab in postmenopausal women with low bone mineral density.

Authors:  Michael R McClung; Andreas Grauer; Steven Boonen; Michael A Bolognese; Jacques P Brown; Adolfo Diez-Perez; Bente L Langdahl; Jean-Yves Reginster; Jose R Zanchetta; Scott M Wasserman; Leonid Katz; Judy Maddox; Yu-Ching Yang; Cesar Libanati; Henry G Bone
Journal:  N Engl J Med       Date:  2014-01-01       Impact factor: 91.245

4.  Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression.

Authors:  Gisela Ruiz Heiland; Karin Zwerina; Wolfgang Baum; Trayana Kireva; Jörg H Distler; Mario Grisanti; Frank Asuncion; Xiadong Li; Michael Ominsky; William Richards; Georg Schett; Jochen Zwerina
Journal:  Ann Rheum Dis       Date:  2010-09-21       Impact factor: 19.103

5.  Dickkopf-1 is a master regulator of joint remodeling.

Authors:  Danielle Diarra; Marina Stolina; Karin Polzer; Jochen Zwerina; Michael S Ominsky; Denise Dwyer; Adelheid Korb; Josef Smolen; Markus Hoffmann; Clemens Scheinecker; Desiree van der Heide; Robert Landewe; Dave Lacey; William G Richards; Georg Schett
Journal:  Nat Med       Date:  2007-01-21       Impact factor: 53.440

6.  Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts.

Authors:  Cristina Vincent; David M Findlay; Katie J Welldon; Asiri R Wijenayaka; Timothy S Zheng; David R Haynes; Nicola L Fazzalari; Andreas Evdokiou; Gerald J Atkins
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

7.  Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis.

Authors:  Heiner Appel; Gisela Ruiz-Heiland; Joachim Listing; Jochen Zwerina; Martin Herrmann; Ruediger Mueller; Hildrun Haibel; Xenofon Baraliakos; Axel Hempfing; Martin Rudwaleit; Joachim Sieper; Georg Schett
Journal:  Arthritis Rheum       Date:  2009-11

8.  Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis.

Authors:  Nicole C Walsh; Susan Reinwald; Catherine A Manning; Keith W Condon; Ken Iwata; David B Burr; Ellen M Gravallese
Journal:  J Bone Miner Res       Date:  2009-09       Impact factor: 6.741

Review 9.  Sclerostin Inhibition in the Management of Osteoporosis.

Authors:  Natasha M Appelman-Dijkstra; Socrates E Papapoulos
Journal:  Calcif Tissue Int       Date:  2016-03-26       Impact factor: 4.333

10.  Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

Authors:  Xiao-Xiang Chen; Wolfgang Baum; Denise Dwyer; Michael Stock; Kay Schwabe; Hua-Zhu Ke; Marina Stolina; Georg Schett; Aline Bozec
Journal:  Ann Rheum Dis       Date:  2013-05-10       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.